Revance Therapeutics, a biotechnology company focused on aesthetic and therapeutic offerings including a next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, has signed a definitive agreement to acquire Hint, a privately held company doing business under the name HintMD, which has created an integrated financial technology (fintech) platform for the aesthetics industry. The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions, including receipt of approval of the requisite HintMD stockholders.
In addition to credit card processing, the HintMD fintech platform has the ability to support patient subscriptions, loyalty programs and third-party services. “The strategic acquisition of HintMD would augment Revance’s strong aesthetics product portfolio with an innovative fintech platform to transform both the practice and patient experience and deliver real value,” said Mark Foley, president and CEO of Revance. “This transaction could grow our total U.S. aesthetics market opportunity to more than $2.6 billion, which we believe we can access through our planned commercial infrastructure. Marketing the HintMD platform, in combination with the RHA Collection of dermal fillers and our investigational neuromodulator product, DaxibotulinumtoxinA for Injection, upon approval, would position us as a true industry innovator.”
